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presented in the guideline. A systematic review was performed on all the information 
about the dosage and frequency of administration found in the summary of product 
characteristics of the different products included in the treatment algorithms. Current 
pricing and reimbursement conditions in Spain of every biologic and chemotherapy 
drug considered in the guidelines were checked. Results: The first scenario, which 
places bevacizumab as first and second line treatment (concept of continuum of 
care) and anti-EGFR antibody as third line out of the four lines considered, yields an 
estimated OS of 20.2 months and total cost of 52,000€ per patient. The second scenario, 
which places bevacizumab as first line treatment and includes anti-EGFR antibody as 
second line in order to rescue the patients who have failed in the previous treatment, 
results in an estimated OS of 25.0 months and total cost of 50,000€ per patient. Finally, 
the third scenario places anti-EGFR antibody available for WT RAS patients as first 
line treatment and bevacizumab as second line out of three lines. When cetuximab is 
chosen as the anti-EGFR first line therapy, estimated OS is 33.1 months and the total 
cost does not exceed 40,000€ . ConClusions: This analysis not only demonstrates 
that the use of more agents does not always assure a better clinical result, but that 
the use of cetuximab as first line treatment in WT RAS mCRC patients stands as the 
most efficient and cost-effective alternative maximizing OS.
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objeCtives: Several platinum-based combination therapies can be used for the 
treatment of non-small lung cancer. According to a recent review, there is no clearly 
superior treatment in terms of effectiveness, the objective of our current study 
was to determine whether treatment with oral vinorelbine plus cisplatin can be 
potentially cost saving for payers, compared to treatment with pemetrexed and cis-
platin. Methods: Considering the similar efficacy results of both treatment options 
in non-squamous non-small cell lung cancer patients (NS-NSCLC), as reported in a 
randomized phase II study (NAVoTRIAL01), a cost minimization analysis was con-
ducted across 12 European countries (Austria, Czech republic, Denmark, Finland, 
France, Germany, Greece, Norway, Slovak Republic, Spain, Switzerland, the UK). This 
analysis adopted the perspective of the National Health Service. Costs considered 
were those related to anticancer drugs, administration settings (i.e. out-patient/in-
patient/at home), serious adverse events and concomitant medications. All relevant 
costs were calculated based on country-specific reimbursement procedures and 
official tariffs. Results: Using the perspective of the National Health Service, the 
savings per patient treated with oral vinorelbine ranged from € 1,317 in Denmark 
to € 35,001 in Germany. Expressed as a percentage, it varies from 5% (France) to 
83% (Czech Republic). Pooled average costs for each treatment option across the 
12 countries resulted in an estimated cost saving of € 12,871 per patient favour-
ing treatment with oral vinorelbine plus cisplatin as opposed to treatment with 
pemetrexed plus cisplatin. Sensitivity analysis confirmed the robustness of the 
results. ConClusions: This pan-European economic analysis provides economic 
evidence to support the use of oral vinorelbine instead of pemetrexed in the treat-
ment of NS-NSCLC. Indeed, oral vinorelbine provides similar efficacy and an eas-
ily manageable safety profile at a lower overall cost per patient treated (from the 
perspective of the NHS). These benefits are also supported by a convenient mode 
of administration for the patient.
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objeCtives: The primary objective of this study is to identify the total cost of illness 
(COI) of metastatic NSCLC in the Netherlands during 2006-2012, from a healthcare 
perspective. Secondary objective is to identify whether changes in distribution of 
costs have occurred over the last years. Methods: Patients diagnosed with met-
astatic NSCLC between 1-1-2006 and 31-12-2012, who had full follow-up and no 
registered trial participation were included. Patient charts were provided, and a 
structured chart review was performed using a case report form. Data collection 
started after diagnosis of metastatic NSCLC and ended at patient’s death. Data were 
collected of outpatient visits, clinical attendance, oncolytic drug use, imaging, lab 
tests, radiotherapy and surgery data. Results: In total 65 patients were included 
in this study. On average patients had 22.2 outpatient visits and 14.1 inpatient days. 
Diagnostic lab tests and imaging procedures were performed respectively 18.7 and 
13.0 times on average. Oncolytic drugs were used by 75% of patients; average 6.3 
intravenous administrations and 22.7 subscription days of oral oncolytic drugs. 
Total costs amounted to € 16,304, with oncolytic drugs (€ 6,625) and inpatient days 
(€ 5,104) as the main cost drivers. In comparison with the time-period of 2003-2005 
total treatment expenditures decreased by 53%. Of this total costs of treatment, the 
proportion of costs of oncolytic drugs increased from 16% to 41% and proportion of 
costs for outpatient visits decreased from 52% to 31%. ConClusions: Outcomes 
in this study demonstrate that, compared to a recent study, the average cost for 
metastatic NSCLC has decreased over time in the Netherlands. A shift of main cost 
drivers seem to have taken place from inpatient stays in 2005, to costs of oncolytic 
drugs currently. This shift is possibly related to changes in patient management but 
also due to the increase of total expenditures on oncolytic drugs.
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had to be in unresectable stage IIIB or stage IV and under current anticancer 
treatment at enrollment. The calculations included direct costs for radiotherapy, 
supportive and concomitant medication, involvement of other medical disciplines, 
hospitalisations, transfusions an other more. The total annual cost were in median 
10,098.00€ per patient. In contrast, the median annual cost of BSC in the four inter-
national studies were 29,621.48€ . ConClusions: The results show a significant 
difference in the annual cost from data under real-world-conditions in relation to 
the median cost from the four international studies. A reason for the lower costs 
compared to the referenced studies could be the higher share of less expensive 
outpatient services in the german health system.
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objeCtives: Abiraterone acetate plus predniso(lo)ne (AA+P) and enzalutamide 
(ENZ) are novel anti-androgen therapies for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) that are approved in both the pre-chemother-
apy and post-chemotherapy settings. The aim of this study is to estimate and 
compare the costs associated with two treatment sequences: AA+P followed by 
docetaxel (DOC) chemotherapy and then ENZ (‘AA+P-DOC-ENZ sequence’) versus 
ENZ followed by DOC chemotherapy and then AA+P (‘ENZ-DOC-AA+P sequence’) 
in mCRPC patients with non-visceral metastases. Methods: A health economic 
model has been developed to estimate and compare the cost consequences of 
these two treatment sequences in the UK. Seven health states were considered in 
the model: pre chemotherapy treatment (AA+P or ENZ), active monitoring (before 
and after chemotherapy separately), DOC chemotherapy, post-chemotherapy 
treatment (AA+P or ENZ), best supportive care, and death. Clinical input data 
(e.g., duration of treatment, time to chemotherapy) for the model were derived 
from published pivotal trial results. Costs parameters were derived from avail-
able literature and the manufacturers’ published reimbursement submission 
dossiers. List prices of drugs were used. For each treatment sequence, the model 
estimated total costs and total costs per health state. Results: The total costs 
were estimated to be £75,956 for the ‘AA+P-DOC-ENZ sequence’ and £80,591 for 
the ‘ENZ-DOC-AA+P sequence’ resulting in a total cost difference of £4,636. Pre-
chemotherapy costs of AA+P and ENZ treatment were estimated to be £43,817 
and £48,860, respectively (difference £5,043). With respect to the other health 
states, similar costs were estimated for the two sequences, e.g., post-chemother-
apy costs of AA+P and ENZ treatment were predicted to be £9,481 and £8,974, 
respectively. ConClusions: The results of the health economic model suggest 
that the ‘AA+P-DOC-ENZ sequence’ yields lower total costs than the ‘ENZ – DOC- 
AA+P sequence’ and therefore starting treatment with AA+P may result in cost 
savings.
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objeCtives: Assess the cost-effectiveness of tyrosine kinase inhibitors (TKIs) on an 
EGFR+ NSCLC population under the Brazilian private healthcare system. Methods: 
A cost-effectiveness analysis (CEA), based on a Markov framework with monthly 
cycles, was performed to evaluate costs and effects of gefitinib versus erlotinib 
on an EGFR+ NSCLC population over a 1 year period. Outcomes measured were 
overall survival (OS), progression free survival (PFS), Quality Adjusted Life Years 
(QALYs) and total costs. Direct medical costs were assessed, including treatment 
and genome testing costs. Treatment costs were based on ex-factory prices and 
label defined posologies. Efficacy data was based on a meta-analysis by Gao et 
al. Results: Gefitinib was equivalent to erlotinib regarding effectiveness outcomes, 
showing incremental results of 0, -0.02 and -0.01 for OS, PFS and QALY over a 1 year 
time horizon, respectively. Costs were significantly lower on patients treated with 
gefitinib than on those treated with erlotinib. On a scenario where genome test-
ing was not performed gefitinib showed a total cost of R$ 21,580.56 (US$ 6,916.67) 
while erlotinib showed total costs of R$ 39,393.24 (US$ 12,626.04), resulting in an 
incremental cost of -R$ 17,812.98 (-US$ 5,709.29). Genome testing added R$ 1,000.00 
(US$ 320.51) to both arms, resulting in R$ 22,580.56 (US$ 7,237.36) and R$ 40,393.24 
(US$ 12,946.55). ConClusions: Regarding effectiveness, both TKIs showed a similar 
profile. Those results are confirmed by a recent meta-analysis by Haaland et al. 
Therefore, in this economic model gefitinib and erlotinib showed similar efficacy 
profile with gefitinib representing a less costly treatment choice than erlotinib for 
the Brazilian private healthcare system.
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objeCtives: ESMO Clinical Guidelines for metastatic Colorectal Cancer treatment 
(mCRC) were updated in 2014. The objective is to assess the clinical (measured by 
overall survival, OS) and economic implications of its recommendations from the 
Spanish national healthcare system view. Methods: A calculator was designed in 
order to analyze and compare the clinical and economic outcomes of the scenarios 
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should range between 52,061 to 67,684 euros. ConClusions: Ovarian cancer is 
a significant burden to the national health system and to society as a whole. The 
model’s results should provide a more precise quantification of both impacts.
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objeCtives: Cancer has been the first leading cause of death in Taiwan since 1982 
and its incidence is rising year by year. Disease burdens associated with cancers 
are substantial. This study aims to evaluate economic burdens of the top 10 cancers 
during 2003-2012 in Taiwan. Methods: Patients with diagnostic ICD-9-CM codes 
of lung, hepatic, colorectal, breast, oral, gastric, prostate, pancreatic, esophageal, 
and cervical cancer during 2003-2012 were identified as the study cases from the 
National Health Insurance Research Database. The prevalence‐based approach 
was employed to describe medical costs associated with the top 10 cancers. The 
productivity losses resulting from cancer deaths were also estimated by multiply-
ing potential life years lost due to the top 10 cancer deaths by average annual 
wage. Results: Total medical costs for all top 10 cancers were increasing, especially 
for lung and breast cancer. Total medical costs of colorectal cancer were the highest 
before 2008, while costs of lung and breast cancer have become dominant since 2008. 
Drug costs were increasing for most top 10 cancers, especially for lung, hepatic, and 
breast cancer. Inpatient costs accounted for the largest proportion of total medical 
costs for most top 10 cancers, except breast, prostate, and cervical cancers. The 
productivity losses incurred by lung, colorectal, breast, oral, and pancreatic cancers 
showed a slightly increasing trend. Hepatic, oral and lung cancers caused the top 
3 highest productivity losses for male, while breast, lung and colorectal cancer did 
for female. ConClusions: This study demonstrates an increasing trend in medical 
costs reimbursed by the National Health Insurance and mortality costs associated 
with the top 10 cancers. Out-of-pocket medical costs and non-medical costs associ-
ated with cancer treatment need to be included in the future to provide the overall 
picture of economic burdens of the top 10 cancers in Taiwan.
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objeCtives: Cervical cancer is the third most common cancer and the fourth can-
cer cause of death in women in Brazil. Given the high incidence, this disease has a 
considerable financial impact in the health budget.The study objective is to develop 
a cost-of-illness study to measure the cervical cancer social cost based in second-
ary data available for public access, in Brazil. Methods: The total cervical cancer 
social cost was calculated including direct medical costs (outpatient and inpatient), 
non-medical costs (caregiver day hospital), productivity loss due to inability of the 
patient to work, potential life-years lost and income loss due to premature death. 
Annual medical and non-medical costs were extracted from Brazilian official data-
base (DATASUS) based on the average annual costs of the last tree years (2012-2014). 
Inpatient productivity loss was calculated considering the mean length of stay 
reported in DATASUS and the Brazilian minimum wage. Outpatient productivity 
loss was calculated considering that patient would take one to fifteen days off. 
Income loss due to premature death was measured subtracting the Brazilian life 
expectancy by the age of death, also reported in DATASUS, and multiplying by the 
Brazilian annual average wage reported by Brazilian Institute of Geography and 
Statistics. International Classification of Diseases (ICD-10) codes considered in this 
analysis wereC358 and C359. Results: Cervical cancer annual direct and indirect 
cost is BRL 71 millions (outpatient cost: BRL44,608,394; inpatient cost including 
caregiver day hospital: BRL23,697,642; productivity loss (range): BRL7,880,390-
BRL20,146,696). Besides, BRL917 million was annually spent with income loss due 
to premature death. The total potential life-years lost was estimated in 33.898 
years. ConClusions: The results reveal that the cervical cancer cost is high in 
Brazil. Despite these results presented are an approximation of the real disease cost, 
it can be a useful data to improve health management practices and public policies.
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objeCtives: To estimate direct medical costs associated with multiple myeloma (MM) 
in publically insured Chinese patients. Methods: China Health Insurance Research 
Association (CHIRA) claim data containing patients randomly selected from publically 
insured urban residents and workers across China was used to identify patients with 
MM and their insurance claim records in 2013. The pattern of prescribed medica-
tions in the identified patients was used to determine the treatment settings for 
the estimations of direct medical costs. Generalized linear model (GLM) was used to 
assess the impact of treatment settings on the direct medical costs after full adjust-
ment of patient baseline demography, complications, and comorbidities. Results: 
The identified 522 patients with MM were stratified by treatment settings as induc-
tion treatment (n= 172), stem cell transplantation (SCT) (n= 7), first-line treatment 
(n= 186), second-line treatment (n= 71), and palliative care (n= 86). The total medical 
costs associated with treatment settings were RMB 69,126 for induction treatment, 
RMB 102,250 for SCT, RMB 77,871 for first-line treatment, RMB 31,193 for second-line 
treatment, and RMB 23,127 for palliative care, respectively (1 RMB = 0.16 US$). Based 
on the multivariate GLM regression analysis, living in central cities (coefficient 0.319, 
p= 0.042), treatment settings prior to palliative care (induction treatment: coefficient 
1.150, p< 0.001; SCT: coefficient 1.804, p< 0.001; first-line treatment: coefficient 1.062, 
objeCtives: Although the economic burden of brain tumors is potentially impor-
tant, little is known about the cost of these cancers in Canada. The objective of 
this study was to estimate the current economic burden associated with primary 
brain cancers in Canada. Methods: We used a prevalence-based cost-of-ill-
ness framework to estimate the annual cost due to primary brain tumors in the 
Canadian population. In order to retrieve clinical epidemiological and healthcare 
resources utilization data, relevant studies were identified with MEDLINE and 
EMBASE databases and Canadian Cancer statistics databases were consulted. The 
analysis was carried out from a societal perspective. Costs were extracted and 
converted to 2015 prices using the Canadian health component of the consumer 
price index. For each cost category, the estimated quantity for each resource was 
multiplied by the unit cost and then summed to get the total costs attributable to 
brain tumors in Canada. Results: Prevalence of primary brain tumors in Canada 
was estimated to 2,289 prevalent cases. Costs related to productivity losses for 
primary brain tumors represented 46% of the total costs. Direct costs were esti-
mated to 54% of the total costs, of which the costs associated with chemotherapy 
represented 52% of all direct costs, while hospitalization, imagery, medical vis-
its, radiotherapy, surgery and concomitant treatments represented 30%, 5%, 5%, 
4%, 3% and 1% of all direct costs respectively. The total cost of brain tumors in 
Canada was estimated at CAN$321,119,700 and the average cost per patient was 
CAN$140,288. ConClusions: The primary brain cancers are scarce but have high 
societal and economic impacts. This economic burden of primary brain cancers 
provides a comprehensive overview of the costs associated with these conditions.
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objeCtives: Economic evaluation is increasingly important in appraisal of innova-
tions in oncology, requiring accurate costing estimations. The MELISSA study aimed 
at assessing hospitalization costs of metastatic melanoma in France. Methods: 
A retrospective cohort analysis from French Medical Information System Program 
(PMSI, “Programme de Médicalisation des Systèmes d’Information”) for years 2011-
2013 was conducted. The study population consisted of all treatment naïve, incident 
adult patients hospitalized with metastatic melanoma diagnosed from 1 Jan 2011 
with follow-up until 31 Dec 2013 or death, whichever occurred first. Melanoma diag-
nosis and metastatic status was obtained using ICD-10 classification (melanoma: 
C43, metastatic status: C77, C78, C79). Patients were allocated to pre-progression and 
post-progression health states of the disease using progression markers, defined 
with clinical experts as the occurrence of either new or brain metastases, pallia-
tive care, or occurrence of both palliative care and brain metastasis or treatment 
switch, identified by specific ICD-10 code. Mean annual and monthly hospitaliza-
tion costs (primary objective) per patient were estimated using French tariffs and 
production costs, adjusting for annual deaths in both inpatient and outpatient 
settings. Secondary objectives consisted of mean annual/monthly costs of chemo-
therapies/immunotherapies, treatments-associated clinical events, palliative care 
and transportation. Results: The cohort enrolled 8,862 patients. There were 7,332 
patients (53% male) in pre-progression (26,843 hospital stays), 5,062 patients (56% 
male) in post-progression (36,425 hospital stays), and 3,479 hospital deaths. Costs 
expressed as mean annual production costs/patient-year were in pre-progression: 
4,973€ for hospitalization, 23,047€ for chemotherapies/immunotherapies, 4,177€ 
for clinical events and 619€ for transportation. In post-progression: 32,320€ for 
hospitalization, 17,884€ for chemotherapies/immunotherapies, 8,827€ for clinical 
events, 19,894€ for palliative care and 2,536€ for transportation. ConClusions: In 
metastatic melanoma in France, treatment costs accounted for the highest share. 
Except treatments, disease progression was associated with a tangible increase of 
hospitalization and other costs. These estimated hospital costs will be useful to 
populate cost-effectiveness models.
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objeCtives: Ovarian cancer is considered a rare disease but with a high mortality 
rate in women. Among women is the 5th most common cancer in Spain and the 
2nd most frequent gynecological malignant tumour. With a prevalence of 0.011% 
and a 0.007% incidence, it is the sixth leading cause of cancer death when com-
pared to all other cancers and the second of the gynecological cancer in Spain. The 
OvarCost study’s main objective is to estimate ovarian cancer’s burden of disease in 
Spain. The study’s secondary objective is to carry out a literature review regarding 
the disease. Methods: A Markov model was executed via the social perspective 
(direct, health and non-health related, and indirect costs) within a 10 year time 
horizon while taking into account disease prevalence, incidence and mortality. 
The model focused on epithelial ovarian cancer, and all four disease stages were 
taken into account. The data resulted from a literature review, later validated via 
a Delphi round and a physical meeting with an ovarian cancer multidisciplinary 
expert panel. Results: The total cost of cancer in Spain is 9,258 million euros, of 
which 4,224MM correspond to direct health costs (46%) and 5,033MM (54%) to direct 
costs not related to health and indirect costs. Thus, given this data and taking into 
account prevalence data at 1 and 5 years, where ovarian cancer accounted for 1.5% 
and 1.4%, respectively, of total cancers in Spain, our model’s results theoretically 
should range from 138-631 million euros, respectively. Prevalence is 2,633 and 9,322 
patients for 1 and 5 years, respectively. These results amount to a cost per patient 
